References
- Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 58:1688–713
- Agarwal V, Khan MA. (2001). Current status of the oral delivery of insulin. Pharma Tech 25:76–90
- Ansari MJ, Jamil S, Anwer MK, et al. (2014). Development and validation of simple and rapid high performance liquid chromatographic method for routine analysis of human insulin in formulations. Afr J Pharm Pharmacol 8:1018–24
- Cho YW, Flynn M. (1989). Oral delivery of insulin. Lancet 2:1518–9
- Damge C, Vrancks H, Balschmidt P, et al. (1997). Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 86:1407–500
- Eaimtrakarn S, Ramaprasad YV, Ohno T, et al. (2002). Absorption-enhancing effect of labrasol on the intestinal absorption of insulin in rats. J Drug Target 10:255–60
- Eldridge JH, Hammond CJ, Meulbroek JA, et al. (1990). Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release 11:205–14
- Fonte P, Andrade F, Araujo F, et al. (2012). Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol 508:295--314
- Fonte P, Araújo F, Silva C, et al. (2015). Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol Adv (in press). doi:10.1016/j.biotechadv.2015.02.010
- Garcia-Fuentes M, Torres D, Alonso MJ. (2005). New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 296:122–32
- Gowthamarajan K, Kulkarni GT. (2003). Oral insulin—fact or fiction? Resonance 8:38–46
- Illing A, Unruh T. (2004). Investigations on the flow behavior of dispersions of solid triglyceride nanoparticles. Int J Pharm 284:123–31
- Jain D, Panda AK, Majumdar DK. (2005). Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech 6:E100–7
- Jung T, Kamm W, Breitenbach A, et al. (2000). Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake. Eur J Pharm Biopharm 50:147–60
- Korytkowski M. (2002). When oral agents fail: practical barriers to starting insulin. Int J Obesity 26:S18–24
- Lee VH. (1991). Oral route of peptide and protein drug delivery, Chapter 16. In: Vincent HL Lee, ed. Peptide and protein drug delivery. New York: Marcel Dekker Inc., 691–738
- Li CL, Deng YJ. (2004). Oil-based formulations for oral delivery of insulin. J Pharm Pharmacol 56:1101–7
- Liang JF, Yang VC. (2005). Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335:734–8
- Lin YH, Chen CT, Liang HF, et al. (2007). Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology 18:1–10
- Liu H, Tang R, Pan WS, et al. (2003). Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 55:1523–9
- Liu J, Gong T, Wang C, Zhong Z, Zhang Z. (2007). Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 340:153–62
- Morishita M, Takayama K, Machida Y, Nagai T. (1993). Enteral insulin delivery by microspheres in three different formulations using Eudragit L-100 and S-100. Int J Pharm 91:29–37
- Nakamura K, Murray RJ, Joseph JI, et al. (2004). Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics. J Control Release 95:589–99
- Patil A, Raheja V, Damre A. (2010). Simultaneous analysis of intestinal permeability markers, caffeine, paracetamol and sulfasalazine by reverse phase liquid chromatography: a tool for the standardization of rat everted gut sac model. Asian J Pharm Clin Res 3:204–7
- Patki VP, Jagasia SH. (1996). Progress made in noninvasive insulin delivery. Ind J Pharmacol 28:143–51
- Peters K, Müller RH. (1998). Nanosuspensions – a novel formulation of poorly soluble drugs. In: Diederichs JE, Müller RH, eds. Future strategies for drug delivery with particulate systems. Boca Raton: CRC Press, 101–8
- Rahman Z, Zidan S, Khan MA. (2010). Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm 76:127–37
- Ravi Kumar MNV. (2000). Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 3:234–58
- Rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1–27
- Sajeesh S, Sharma CP. (2006). Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nano-particles for oral insulin delivery. Int J Pharm 325:147–54
- Sarmento B, Martins S, Ferreira D, Souto EB. (2007). Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2:743–9
- Shah RB, Ahsan F, Khan MA. (2002). Oral delivery of proteins: Progress and prognostication. Crit Rev Ther Drug Carrier Syst 19:135–69
- Soares S, Fonte P, Costa A, et al. (2013). Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Int J Pharm 456:370–81
- Soltero R, Ekwuribe N. (2001). The oral delivery of protein and peptide drugs – a report. Innovat Pharmaceut Technol 1:106–10
- Spangler RS. (1990). Insulin administration via liposomes. Diabetes Care 13:911–22
- Timmy SA, Victor SP, Sharma CP, Kumari VJ. (2002). Betacyclodextrincomplexed insulin loaded alginate microspheres – oral delivery system. Trends Biomater Artif Organs 15:48–53
- Toorisaka E, Hashida M, Kamiya N, et al. (2005). An enteric-coated dry emulsion formulation for oral insulin delivery. J Control Release 107:91–6
- Wu ZH, Ping QN, Lai JM, Wei Y. (2003). Hypoglycemic effect of polysaccharide-coated insulin liposomes after oral administration in mice. Acta Pharm Sin 38:138–42
- Yang R, Gao RC, Cai CF, et al. (2010). Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem Pharm Bull 58:1195–202
- Yassin AB, Anwer MK, Mowafy HA, et al. (2010). Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 7:398–408
- Yu F, Li Y, Liu CS, et al. (2015). Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin. Int J Pharm 484:181–91
- Zhang J, Fan Y, Smith E. (2009). Experimental design for the optimization of lipid nanoparticles. J Pharm Sci 98:1813–19
- Zhang ZH, Zhang YL, Zhou JP, Lv HX. (2012). Solid lipid nanoparticles modified with stearic acid–octaarginine for oral administration of insulin. Int J Nanomedicine 7:3333–9
- Zhao Y, Trewyn BG, Slowing II, Lin VS. (2009). Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J Am Chem Soc 131:8398–400
- Ziv E, Lior O, Kidron M. (1987). Absorption of protein via the intestinal walls: a quantitative model. Biochem Pharmacol 39:1035–9